The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities

Protein Science

Volumn 22, Issue 12, 2013, Pages 1786-1798

  Aydin, Cihan ^a   Mukherjee, Sourav ^b   Hanson, Alicia M ^b   Frick, David N ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Bifunctional enzyme; Catalytic activity; Dynamic coupling; HCV NS3 4A; Interdomain communication; Protease helicase interaction

Indexed keywords

ADENOSINE TRIPHOSPHATE; HELICASE; MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE; RNA;

AMINO ACID SUBSTITUTION; ARTICLE; AUTOREGULATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA DENATURATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STRUCTURE; HYDROLYSIS; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY MECHANISM; RNA PROCESSING;

BIFUNCTIONAL ENZYME; CATALYTIC ACTIVITY; DYNAMIC COUPLING; HCV NS3/4A; INTERDOMAIN COMMUNICATION; PROTEASE-HELICASE INTERACTION;

AMINO ACID SUBSTITUTION; CARRIER PROTEINS; DNA HELICASES; HEPACIVIRUS; KINETICS; MOLECULAR DYNAMICS SIMULATION; MULTIFUNCTIONAL ENZYMES; PEPTIDE HYDROLASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RNA HELICASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84892910710     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2378     Document Type: Article

References (40)

1. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29(Suppl 1):74-81.
2. Liang TJ, Heller T (2004) Pathogenesis of hepatitis Cassociated hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S62-71.
3. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453-463.
4. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D (2011) Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus. J Viral Hepat 18:305-315.
5. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353- 1363.
6. Frick DN (2007) The hepatitis C virus NS3 protein: A model RNA helicase and potential drug target. Curr Issues Mol Biol 9:1-20.
7. Dahl G, Sandstrom A, Akerblom E, Danielson UH (2007) Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein FEBS J 274:5979-5986.
8. Thibeault D, Massariol MJ, Zhao S, Welchner E, Goudreau N, Gingras R, Llinas-Brunet M, White PW (2009) Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3- NS4A. Biochemistry 48:744-753.
9. Beran RK, Pyle AM (2008) Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem 283:29929-29937.
10. Frick DN, Rypma RS, Lam AM, Gu B (2004) The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently. J Biol Chem 279:1269-1280.
11. Beran RK, Serebrov V, Pyle AM (2007) The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J Biol Chem 282:34913-34920.
12. Yon C, Teramoto T, Mueller N, Phelan J, Ganesh VK, Murthy KH, Padmanabhan R (2005) Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase. J Biol Chem 280: 27412-27419.
13. Chernov AV, Shiryaev SA, Aleshin AE, Ratnikov BI, Smith JW, Liddington RC, Strongin AY (2008) The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. J Biol Chem 283:17270-17278.
14. Shiryaev SA, Chernov AV, Shiryaeva TN, Aleshin AE, Strongin AY (2011) The acidic sequence of the NS4A cofactor regulates ATP hydrolysis by the HCV NS3 helicase. Arch Virol 156:313-318.
15. Appleby TC, Anderson R, Fedorova O, Pyle AM, Wang R, Liu X, Brendza KM, Somoza JR (2011) Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV. J Mol Biol 405:1139-1153.
16. Schiering N, D'Arcy A, Villard F, Simic O, Kamke M, Monnet G, Hassiepen U, Svergun DI, Pulfer R, Eder J, Raman P, Bodendorf U (2011) A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target. Proc Natl Acad Sci U S A 108:21052-21056.
17. Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D (2008) Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A 105:14545-14550.
18. Ding SC, Kohlway AS, Pyle AM (2011) Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus. J Virol 85:4343-4353.
19. Mastrangelo E, Milani M, Bollati M, Selisko B, Peyrane F, Pandini V, Sorrentino G, Canard B, Konarev PV, Svergun DI, de Lamballerie X, Coutard B, Khromykh AA, Bolognesi M (2007) Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein. J Mol Biol 372:444-455.
20. Luo D, Xu T, Hunke C, Gruber G, Vasudevan SG, Lescar J (2008) Crystal structure of the NS3 proteasehelicase from Dengue virus. J Virol 82:173-183.
21. Romano KP, Laine JM, Deveau LM, Cao H, Massi F, Schiffer CA (2011) Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease. J Virol 85:6106-6116.
22. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B (2005) Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 75: 528-537.
23. Hanson AM, Hernandez JJ, Shadrick WR, Frick DN (2012) Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase. Methods Enzymol 511:463-483.
24. Lam AM, Keeney D, Frick DN (2003) Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action. J Biol Chem 278:44514-44524.
25. Umehara T, Fukuda K, Nishikawa F, Sekiya S, Kohara M, Hasegawa T, Nishikawa S (2004) Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. Nucleic Acids Symp Ser (Oxf) 48:195-196.
26. Vaughan R, Li Y, Fan B, Ranjith-Kumar CT, Kao CC (2012) RNA binding by the NS3 protease of the hepatitis C virus. Virus Res 169:80-90.
27. He Y, Weng L, Li R, Li L, Toyoda T, Zhong J (2012) The N-terminal helix alpha(0) of hepatitis C virus NS3 protein dictates the subcellular localization and stability of NS3/NS4A complex. Virology 422:214-223.
28. Horner SM, Park HS, Gale M Jr (2012) Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix alpha0. J Virol 86:3112-3120.
29. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, Graham B, Hiscock SD, Murray CW, Pathuri P, Rich SJ, Richardson CJ, Williams PA, Jhoti H (2012) Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 8:920-925.
30. Jennings TA, Mackintosh SG, Harrison MK, Sikora D, Sikora B, Dave B, Tackett AJ, Cameron CE, Raney KD (2009) NS3 helicase from the hepatitis C virus can function as a monomer or oligomer depending on enzyme and substrate concentrations. J Biol Chem 284:4806-4814.
31. Mackintosh SG, Lu JZ, Jordan JB, Harrison MK, Sikora B, Sharma SD, Cameron CE, Raney KD, Sakon J (2006) Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus. J Biol Chem 281:3528-3535.
32. Case DA, Cheatham TE III, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688.
33. Belon CA, Frick DN (2009) Fuel specificity of the hepatitis C virus NS3 helicase. J Mol Biol 388:851-864.
34. Romano KP, Ali A, Royer WE, Schiffer CA (2010) Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A 107:20986-20991.
35. Wittekind M, Weinheirner S, Zhang Y, Goldfarb V (2002) Modified forms of hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: Inhibitor complexes. In: United States Patent Applications Publication. United States of America, p. 26.
36. Palmier MO, Van Doren SR (2007) Rapid determination of enzyme kinetics from fluorescence: Overcoming the inner filter effect. Anal Biochem 371:43-51.
37. Seiwert SD, Kossen K, Pan L, Liu J, Buckman BO (2011) Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227). In: Antiviral Drugs. John Wiley & Sons, Inc., pp. 257-271.
38. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 46:1-265.
39. Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez JJ, Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN (2012) Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. Nucleic Acids Res 40:8607-8621.
40. Lam AM, Rypma RS, Frick DN (2004) Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding. Nucleic Acids Res 32:4060-4070.